MedTrace Logo

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

NCT05656248 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-04

No results posted yet for this study

Summary

The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).

Conditions

  • Myeloid Neoplasm

Interventions

DRUG

CPX-351

Given Intraveneously (IV)

DRUG

MHA

Given Intrathecal (IT)

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HSCT

Sponsors & Collaborators

Principal Investigators

  • Raul C. Ribeiro, MD · St. Jude Children's Research Hospital

  • Marcin Wlodarski, MD, PhD · St. Jude Children's Research Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2025-08-28
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656248 on ClinicalTrials.gov